A method of determining the effectiveness of a GPC3 targeted therapeutic therapy for cancer in a patient or patient prior to receiving GPC3 targeted therapeutics therapy, or determining continuation of GPC3 targeted therapeutics therapy for a patient, wherein the patient prior to receiving GPC3 targeted therapeutics therapy and/or measuring the number of immune cells or the expression level of a molecule expressed on the immune cells in a biological sample isolated from a patient who has received GPC3 targeted therapeutic agent therapy, wherein the cell number or expression level is a predetermined value Disclosed is a method for determining that a GPC3 targeted therapeutic agent is effective, or for determining continuation of a GPC3 targeted therapeutic agent therapy. Also disclosed are GPC3 targeted therapeutics or formulations for administration to a patient in which it has been determined that GPC3 targeted therapeutics therapy is effective, or it has been determined to continue GPC3 targeted therapeutics therapy.
展开▼
